Autolus Therapeutics plc
AUTL$614M
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaLONDON647 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
AUTL News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
AUTO1
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
AUTO3 (CD19/22 CAR T cells
B Acute Lymphoblastic Leukemia
AUTO4
T Cell Non-Hodgkin Lymphoma
Obecabtagene autoleucel
Lupus Nephritis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AUTO1 | Phase 2 | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | - | - |
AUTO3 (CD19/22 CAR T cells | Phase 2 | B Acute Lymphoblastic Leukemia | - | - |
AUTO4 | Phase 2 | T Cell Non-Hodgkin Lymphoma | - | - |
Obecabtagene autoleucel | Phase 2 | Lupus Nephritis | - | - |
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply